Natera announces national commercial coverage for Fetal RhD NIPT

Natera (NTRA), announced a new policy for commercial coverage of its cfDNA Fetal RhD noninvasive prenatal test, Fetal RhD NIPT from one of the largest payors in the United States. Effective as of Jan. 2025, the policy notes that coverage of fetal RhD testing is available when a pregnancy may be at risk for alloimmunization, when paternal antigen typing is unavailable or heterozygous, and if a patient declines amniocentesis or it is not recommended for the pregnancy. Up to 15 percent of pregnant patients are RhD-negative1. When the maternal blood type is RhD-negative and the fetal blood type is RhD-positive, antibodies can develop OR alloimmunization that can lead to hemolytic disease of the fetus and newborn. Natera’s Fetal RhD NIPT can be performed as early as nine weeks gestation and determines fetal RhD status from the blood of a pregnant patient. It is offered through the Company’s women’s health suite of products, which includes Panorama, the no. 1 ordered NIPT in the U.S. “These new policies expand access to important testing that can prevent unnecessary medical treatment in pregnancies,” said Ramesh Hariharan, PhD, General Manager of Women’s Health at Natera. “Broadening commercial coverage to include fetal RhD testing reinforces the importance of this offering and the benefits it can bring to pregnant patients nationwide.”